热线电话:+86 512 6799 8818

在线咨询

TOP

*姓名

*电话

邮箱

咨询内容

*验证码

联系销售


Sales Image

联系销售助理


Sales Assistant Image

联系PM


PM Image
Consult Now
[Client Article Interpretation] New "force-bone" coupling switch in bone remodeling: Discovery of the Piezo1-ZBP1 pathway and validation of gene manipulation tools
2026-08-14
[Client Article Interpretation] New "force-bone" coupling switch in bone remodeling: Discovery of the Piezo1-ZBP1 pathway and validation of gene manipulation tools
This study reveals that the mechanosensitive channel Piezo1 in macrophages converts mechanical stimuli into inflammatory bone resorption via the ZBP1 signaling axis, establishing a novel molecular switch for bone remodeling. GentleGen provided lentiviral packaging services for this research, supporting the validation of gene manipulation tools.
View More
GentleGen Frontier Focus: By 2026, sgRNA will evolve from a "navigator" to an "operating system" for gene editing.
2026-08-10
GentleGen Frontier Focus: By 2026, sgRNA will evolve from a "navigator" to an "operating system" for gene editing.
In 2026, sgRNA has achieved a dual breakthrough: multiplexed sgRNA-mediated协同 targeting has reached >99% efficiency, chemical modifications have fully armored guide RNAs, while the TDO mechanism has revealed a new source of off-target effects, and ΨDNA has shattered the dogma that “guides must be RNA.” sgRNA is evolving from a mere navigation device for gene scissors into the core control layer of the entire editing system.
View More
Multi-point breakthroughs in siRNA extrahepatic delivery technology by 2026—GentleGen's full-chain technical support
2026-08-10
Multi-point breakthroughs in siRNA extrahepatic delivery technology by 2026—GentleGen's full-chain technical support
In 2026, the PNP platform received Phase II clinical validation, IVSA demonstrated the potential to transform the liver into a “biopharmaceutical factory,” and lipid‑siRNA conjugates achieved breakthroughs in crossing the blood–brain barrier—marking multiple advances in extrahepatic siRNA delivery. GentleGen provides end‑to‑end technical support covering everything from sequence design to high‑throughput screening, helping the field move beyond the question of “whether” extrahepatic delivery is possible to “how” to do it better.
View More
When AI can mass-produce antibodies, what is the core bottleneck?
2026-07-31
When AI can mass-produce antibodies, what is the core bottleneck?
The past 20+ years have seen dramatic shifts in biopharma and synthetic biology. New drug modalities—from small molecules and antibodies to cell and gene therapies—keep emerging. But a single challenge endures: how do we efficiently get to high‑quality leads?
View More
GentleGen × Weixin Computing Strategic Cooperation, AI + Automated Wet and Dry Closed Loop, Jointly Creating a New Paradigm for Drug R&D!
2026-07-24
GentleGen × Weixin Computing Strategic Cooperation, AI + Automated Wet and Dry Closed Loop, Jointly Creating a New Paradigm for Drug R&D!
GentleGen and WeComput have formed a strategic partnership to bridge AI-driven molecular design with automated experimental validation, establishing a closed‑loop iteration of "design → build → test → data". This collaboration shifts drug discovery from random trial‑and‑error to precision engineering, accelerating the translation of life‑science tools from the laboratory to industrial application.
View More
One-Stop Oligonucleic acid Service: A Full-chain Solution from Target Screening to Cellular Validation!
2026-07-17
One-Stop Oligonucleic acid Service: A Full-chain Solution from Target Screening to Cellular Validation!
Oligonucleotide drug development typically requires screening dozens to hundreds of sequences, followed by multiple rounds of modification and delivery optimization. This process often involves coordination with multiple vendors, making it difficult to trace issues back to their source. GentleGen's one‑stop platform integrates the entire workflow – from target assessment, sequence design, and synthesis/purification to cell‑based validation – enabling a seamless transition from concept to candidate molecule.
View More
AI Antibodies from Sequence to Protein: Fully Automated, Significantly Reducing R&D Budgets!
2026-07-15
AI Antibodies from Sequence to Protein: Fully Automated, Significantly Reducing R&D Budgets!
AI‑designed antibodies are easy to generate, but high‑throughput validation remains a major bottleneck. GentleGen's fully automated platform enables one‑stop delivery from gene to antibody: IgG monoclonal antibodies at 48.9 USD/clones, nanobodies at 28.9 USD/clones, each with 800 µL of supernatant included – making high‑throughput AI screening a routine laboratory practice.
View More
ASCO 2026 Insights: The Bispecific Antibody Wave Accelerates Antibody Drug Iteration, Automated Gene Services Lay a Solid Foundation for Innovation!
2026-07-15
ASCO 2026 Insights: The Bispecific Antibody Wave Accelerates Antibody Drug Iteration, Automated Gene Services Lay a Solid Foundation for Innovation!
The bispecific antibody Yiwosi presented updated survival data in lung cancer at ASCO 2026, becoming the first global Phase III trial to achieve positive results on dual primary endpoints. Bispecific antibody development relies heavily on high‑quality gene synthesis, and GentleGen's fully automated platform delivers in just 10 days, supporting innovation at the source.
View More
Nature Sub-journal (IF=19.4) | GentleGen Supports National University of Singapore in Building the LySE System, Ending the Dilemma of Speed and Accuracy in Directed Evolution!
2026-07-14
Nature Sub-journal (IF=19.4) | GentleGen Supports National University of Singapore in Building the LySE System, Ending the Dilemma of Speed and Accuracy in Directed Evolution!
A team from the National University of Singapore has developed the LySE directed evolution platform, as reported in Nature Microbiology. By engineering the T7 phage DNA polymerase, the platform enables hypermutation with precise targeting of genes of interest. GentleGen provided the core gene gox0313 with this study, supporting the validation of key platform functions. With just five rounds of evolution, the platform achieved a 25‑fold increase in drug resistance and a 50.9% improvement in PET degradation efficiency, and supports continuous evolution of gene clusters of up to 40 kb.
View More
Is your siRNA "silent" again? No, silence is useless! A must-read guide for researchers to avoid the pitfalls of oligonucleic acid testing!
2026-06-26
Is your siRNA "silent" again? No, silence is useless! A must-read guide for researchers to avoid the pitfalls of oligonucleic acid testing!
For small nucleic acid tools such as siRNA and shRNA, this guide covers best practices to avoid common pitfalls across the entire workflow – from sequence design and chemical modification to transfection experiments – including target selection, off‑target control, proper controls, and in vivo delivery strategies. GentleGen's one‑stop service platform deeply integrates core capabilities including target evaluation, sequence design, synthesis and purification, activity screening, and modification conjugation, delivering an "idea‑to‑reality" R&D experience for nucleic acid drug development.
View More
123
Pre-sales consulting

Pre-sales consulting

A more reliable solution for your needs.
Download

Download

Welcome to our product library.
Sales network

Sales network

Complete sales and service network to ensure product quality.
Event Promotions

Event Promotions

Add to cart now and enjoy this shopping extravaganza!